{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6"},{"groupId":"OG001","value":"3.9"},{"groupId":"OG002","value":"5.5"}]}],"title":"CIN grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2"},{"groupId":"OG001","value":"1.2"},{"groupId":"OG002","value":"2.2"}]}],"title":"FN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"},{"groupId":"OG001","value":"2.1"},{"groupId":"OG002","value":"4.7"}]}],"title":"CIN/FN-related chemotherapy disturbance"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0"},{"groupId":"OG001","value":"5.8"},{"groupId":"OG002","value":"9.3"}]}],"title":"Composite^"}],"denoms":[{"counts":[{"groupId":"OG000","value":"380"},{"groupId":"OG001","value":"784"},{"groupId":"OG002","value":"419"}],"units":"Participants"}],"description":"Objective 5: To describe the distribution of chemotherapy dose delays and reductions, surgery delays and cancellations, radiotherapy delays, dose reductions, and cancellations, and mortality (GCSF-related; FN-related; cancer-related; not related to GCSF, FN, or cancer; all-cause); and estimate the time-to-event for such events over the course of EP2006 treatment.\n\nTable presents incidences of outcomes on a cycle level by study drug duration. \\^Composite outcome includes CIN grade 4, FN, CIN/FN-related hospitalization and CIN/FN-related chemotherapy disturbance\n\nCIN: Chemotherapy-Induced Neutropenia; FN: Febrile Neutropenia;","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN with 1-3 days of study drug duration.","id":"OG000","title":"EP2006: 1-3 Days Duration"},{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN with 4-5 days of study drug duration.","id":"OG001","title":"EP2006: 4-5 Days Duration"},{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN with \\>=6 days of study drug duration.","id":"OG002","title":"EP2006: >=6 Days Duration"}],"paramType":"NUMBER","populationDescription":"Evaluable sample by study drug duration. As these are cycle-level analyses and since patients can be in more than one category over the course of the study, the sum of patients of all three categories may exceed the sample size.","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"Incidence of Outcomes by Study Drug Duration: Cycle Level","type":"PRIMARY","unitOfMeasure":"percentage of participants"}